Aykut Uren

Rockville, MD, United States of America

Aykut Uren

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 64(Granted Patents)


Location History:

  • Baltimore, MD (US) (2003 - 2014)
  • Rockville, MD (US) (2016 - 2017)

Company Filing History:


Years Active: 2003-2017

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Aykut Uren: Innovator in Cancer Therapy

Introduction

Aykut Uren is a prominent inventor based in Rockville, MD (US), known for his significant contributions to cancer therapy. With a total of 8 patents to his name, Uren has focused on developing innovative treatments for Ewing's sarcoma, a rare type of cancer.

Latest Patents

Uren's latest patents include groundbreaking work on the targeting of EWS-FLI1 as an anti-tumor therapy. He has developed peptides and compounds that function as EWS-FLI1 protein inhibitors, which are crucial in treating the Ewing's sarcoma family of tumors. Additionally, he has provided methods and compositions for treating these tumors, emphasizing the utility of EWS-FLI1 protein inhibitors in cancer treatment.

Career Highlights

Throughout his career, Aykut Uren has worked with esteemed institutions such as Georgetown University and the National Institutes of Health, a component of the US Department of Health & Human Services. His work has been instrumental in advancing the understanding and treatment of Ewing's sarcoma.

Collaborations

Uren has collaborated with notable colleagues, including Jeffrey A. Toretsky and Milton L. Brown, further enhancing the impact of his research in the field of oncology.

Conclusion

Aykut Uren's innovative work in cancer therapy, particularly in targeting EWS-FLI1, showcases his dedication to improving treatment options for patients with Ewing's sarcoma. His contributions continue to influence the landscape of cancer research and therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…